$200 million upfront payment received in December 2022 from CSL collaboration
Achieved $90 million in development milestones in March 2023 under CSL collaboration
ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan
Multiple patients enrolled in ARCT-810 Phase 2 multiple ascending dose trial for OTC deficiency
ARCT-032 Phase 1 Cystic Fibrosis trial initiated and enrollment of first two cohorts successfully completed
Investor conference call at 4:30 p.m. ET today
Earnings Call: Tuesday, March 28, 2023 @ 4:30 pm ET
Domestic: 1-877-407-0784
International: 1-201-689-8560
Conference ID: 13735876
Webcast: Link
https://finance.yahoo.com/news/arcturus-therapeutics-announces-fourth-quarter-200100953.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.